Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

GSK and Genmab receive FDA priority review for Arzerra BLA

Dec. 19, 2013

Chimeric antigen receptor therapy for pediatric ALL targets the TSLPR

Dec. 18, 2013

arGEN-X reports findings from dose-escalation part of phase Ib study of ARGX-110

Dec. 18, 2013

Researchers from the University of California present two novel ROR1-targeting therapies

Dec. 18, 2013

Final phase I lymphoma results presented for antibody-drug conjugates from Genentech

Dec. 17, 2013

KaloBios Pharmaceuticals presents phase I results for KB-004

Dec. 16, 2013

ImmunoCellular Therapeutics reports phase II data for ICT-107

Dec. 16, 2013

Otlertuzumab combined with rituximab shows promise in lymphocytic leukemia

Dec. 13, 2013

Final results presented for glioblastoma multiforme trial of Cotara

Dec. 13, 2013

Treatment phase of MGN-1703 safety trial completed

Dec. 12, 2013

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...